B3-02: Randomized, double-blind, multicenter, parallel-group, Phase II study of gefitinib (IRESSA) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naïve patients with advanced non-small-cell lung cancer and poor performance status (INSTEP)
Glenwood D. Goss, David Raymond Ferry, Scott Andrew Laurie et al. · Journal of Thoracic Oncology · 2007
Cited by 14 works. doi:10.1097/01.jto.0000283154.03863.ae